{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:10:51Z","timestamp":1790611851486,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00418","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T14:15:41Z","timestamp":1585232141000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial"],"prefix":"10.3389","volume":"11","author":[{"given":"Miriam","family":"Ros\u00e1s-Umbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ruiz-Riol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Marszalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pep","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Manzardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samandhy","family":"Cede\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the BCN02 study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nm.2111","article-title":"HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects","volume":"16","author":"Buz\u00f3n","year":"2010","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3851\/IMP1917","article-title":"Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study","volume":"17","author":"Llibre","year":"2011","journal-title":"Antivir Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e27864","DOI":"10.1371\/journal.pone.0027864","article-title":"Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on t cells latently infected","volume":"6","author":"Guti\u00e9rrez","year":"2011","journal-title":"PLoS ONE"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1097\/QAD.0b013e3283584521","article-title":"The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients","volume":"26","author":"Vallejo","year":"2012","journal-title":"AIDS"},{"key":"B6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/QAI.0b013e31823fd1f2","article-title":"No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy","volume":"59","author":"Gandhi","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"eaan8848","DOI":"10.1126\/scitranslmed.aan8848","article-title":"A randomized controlled safety\/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection","volume":"9","author":"Sneller","year":"2017","journal-title":"Sci Transl Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"166ra2","DOI":"10.1126\/scitranslmed.3004682","article-title":"A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication","volume":"5","author":"Garc\u00eda","year":"2013","journal-title":"Sci Transl Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1097\/QAD.0b013e3282fdce94","article-title":"Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)","volume":"22","author":"Autran","year":"2008","journal-title":"AIDS"},{"key":"B11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1086\/655468","article-title":"AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein","volume":"202","author":"Schooley","year":"2010","journal-title":"J Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.eclinm.2019.05.009","article-title":"Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)","volume":"11","author":"Mothe","year":"2019","journal-title":"EClinicalMedicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"21171","DOI":"10.7448\/IAS.20.1.21171","article-title":"Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects","volume":"20","author":"Hancock","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1182\/blood-2016-01-678144","article-title":"The clinical applications of genome editing in HIV","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"B16","first-page":"454","article-title":"Potential non-oncological applications of histone deacetylase inhibitors","volume":"3","author":"Ververis","year":"2011","journal-title":"Am J Transl Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1004071","DOI":"10.1371\/journal.ppat.1004071","article-title":"Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing","volume":"10","author":"Wei","year":"2014","journal-title":"PLoS Pathog"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1004473","DOI":"10.1371\/journal.ppat.1004473","article-title":"Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy","volume":"10","author":"Elliott","year":"2014","journal-title":"PLoS Pathog."},{"key":"B21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/infdis\/jiu155","article-title":"HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat","volume":"210","author":"Archin","year":"2014","journal-title":"J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo","volume":"11","author":"S\u00f8gaard","year":"2015","journal-title":"PLoS Pathog"},{"key":"B23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3109\/10428194.2012.711829","article-title":"Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin","volume":"54","author":"Kim","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","first-page":"993","DOI":"10.4161\/hv.23800","article-title":"Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation","volume":"9","author":"Rasmussen","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV"},{"key":"B26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","article-title":"Stimulation of HIV-1-Specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation","volume":"36","author":"Shan","year":"2012","journal-title":"Immunity"},{"key":"B27","article-title":"Therapeutic vaccines after early ART: impact on reservoir","volume-title":"Oral session on Therapeutic Vaccines and Cure Strategies at the Joint Keystone Symposia on HIV Vaccines and Functional Cures and the Eradication of HIV, 2019 Mar 24\u201328","author":"Mothe","year":"2019"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1004287","DOI":"10.1371\/journal.ppat.1004287","article-title":"Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-Lymphocytes","volume":"10","author":"Jones","year":"2014"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1005545","article-title":"A subset of latency-reversing agents expose HIV-infected resting CD4 + T-cells to recognition by cytotoxic T-lymphocytes","volume":"12","author":"Jones","year":"2016"},{"key":"B30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"key":"B31","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/infdis\/jis379","article-title":"Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection","volume":"206","author":"Yang","year":"2012","journal-title":"J Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.phrs.2018.10.023","article-title":"T cell toxicity of HIV latency reversing agents","volume":"139","author":"Zhao","year":"2019","journal-title":"Pharmacol Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"30749","DOI":"10.1038\/srep30749","article-title":"The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function","volume":"6","author":"Clutton","year":"2016","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jinf.2017.09.004","article-title":"Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs","volume":"75","author":"Tapia","year":"2017","journal-title":"J Infect"},{"key":"B35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2217\/imt-2019-0092","article-title":"Can we just kick-and-kill HIV: possible challenges posed by the epigenetically controlled interplay between HIV and host immunity","volume":"11","author":"Ruiz-Riol","year":"2019","journal-title":"Immunotherapy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1005782","DOI":"10.1371\/journal.ppat.1005782","article-title":"Histone deacetylase inhibitors enhance CD4 T Cell susceptibility to NK cell killing but reduce NK Cell function","volume":"12","author":"Pace","year":"2016","journal-title":"PLoS Pathog"},{"key":"B37","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fimmu.2016.00356","article-title":"HIV latency-reversing agents have diverse effects on natural killer cell function","volume":"7","author":"Garrido","year":"2016","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0141456","DOI":"10.1371\/journal.pone.0141456","article-title":"A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART","volume":"10","author":"G\u00f3mez","year":"2015","journal-title":"PLoS ONE"},{"key":"B39","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/infdis\/jiv022","article-title":"Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir","volume":"212","author":"Sung","year":"2015","journal-title":"J Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ebiom.2017.01.034","article-title":"Factors associated with the control of viral replication and virologic breakthrough in a recently infected HIV-1 controller","volume":"16","author":"Walker-Sperling","year":"2017","journal-title":"EBioMedicine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"10543","DOI":"10.1128\/JVI.00793-10","article-title":"Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B*2705-restricted CD8 + T Cells","volume":"84","author":"Payne","year":"2010","journal-title":"J Virol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.3389\/fimmu.2018.02443","article-title":"Phenotype, polyfunctionality, and antiviral activity of in vitro stimulated CD8+ T-cells from HIV+ subjects who initiated cART at different time-points after acute infection","volume":"9","author":"Salido","year":"2018","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/infdis\/jiu534","article-title":"Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected","volume":"211","author":"Ruiz-Riol","year":"2015","journal-title":"J Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e01436","DOI":"10.1128\/JVI.01436-18","article-title":"Mechanisms of abrupt loss of virus control in a cohort of previous HIV controllers","volume":"93","author":"Rosas-Umbert","year":"2019","journal-title":"J Virol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.immuni.2008.10.010","article-title":"Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control","volume":"29","author":"Migueles","year":"2008","journal-title":"Immunity"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T14:15:46Z","timestamp":1585232146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2020.00418"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00418","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"article-number":"418"}}